Our new Japanese recruitment team delivers volunteer panels - already!

Posted:
16
December 2004

Volunteers enjoying a study

Richmond Pharmacology's new dedicated Japanese recruitment team have successfully delivered 2 Japanese panels for Bridging Studies in November and December this year. We are already ahead of target for our Japanese/Caucasian Bridging Studies requirements in 2005.As a result of the continued growth in the demand for Bridging Studies, Richmond Pharmacology have developed a dedicated in-house approach to the recruitment of Japanese volunteer panels.Wendy Galloway, Head of Volunteer Recruitment, commented: “We recognised the need to introduce a stronger means of recruiting Japanese volunteers. Consequently, in September we recruited 5 bilingual Japanese recruitment managers and have introduced a specialist marketing strategy to support this. I am delighted with the results – in just 2 months since the launch we have successfully delivered 2 Japanese volunteer panels. Our campaigns currently stretch across the UK and Germany and through this approach we are already ahead of target for the New Year's requirements. This means we continue to offer our clients a volunteer recruitment guarantee on every Phase I study.”Richmond Pharmacology is Europe's largest provider of Japanese/Caucasian Bridging Studies and has a dedicated Japanese recruitment brand and department. For more information click here.

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more